Source: Annual Congress 2003 - Lung cancer management
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
P. S. Barradas, A. S. Oliveira, A. M. Costa, A. M. Figueiredo, F. J. Barata, A. P. Alves, M. M. Cristovao, M. J. S. Melo (Lisboa, Coimbra, Portugal). Docetaxel as second-line chemotherapy (CT) in advanced non small cell lung cancer(NSCLC) patients (pts): does it really work?. Eur Respir J 2003; 22: Suppl. 45, 326

Member's Comments

No comment yet.

Related content which might interest you: Gemcitabine (G) or vinorelbine (V)? What's the best drug in combination with a platinium-derivative for the treatment of locally advanced and metastatic non small cell lung cancer (NSCLC)? A 6 years retrospective study Source: Eur Respir J 2003; 22: Suppl. 45, 527s Year: 2003 Second line chemotherapy with cisplatin (C) plus paclitaxel (P) for chemo refractory and resistant SCLC patients (pts). Did it change the overall disease’s prognosis? Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003 Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001 Once a day (QD) thoracic radiotherapy (XRT) for patients with limited stage small-cell lung cancer (SCLC) treated concurrently with etoposide and cisplatin (EP): results of a single institution retrospective experience Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Treatment of advanced and metastatic non small cell lung carcinoma (NSCLC) with a new schedule of gemcitabine (GEM) plus cisplatin (CDDP) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 Different efficacy between carboplatin (Cpl) and gemcitabine (Gem) on median survival time of elderly non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Carboplatin (C), paclitaxel (T) and etoposide (E) and early concurrent thoracic radiotherapy (TRT) for patients with limited disease small cell lung cancer (LD-SCLC): a Dutch multicentre phase 2 study Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Low dosage chemotherapy, with carboplatin (CBDCA) and vinorelbine (VNR), in advanced nonsmall cell lung cancer (NSCLC) in patients with low performance status Source: Eur Respir J 2003; 22: Suppl. 45, 528s Year: 2003 Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC). Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Front-line weekly gemcitabine (G) for unfit or elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007